GLP-1 Vision Loss (Ozempic / Wegovy NAION)
Published Updated
By People's Justice
What happened
The U.S. Judicial Panel on Multidistrict Litigation creates In re GLP-1 RAs NAION Products Liability Litigation, MDL No. 3163, in the Eastern District of Pennsylvania before Judge Karen Marston, keeping the vision-loss claims separate from an earlier GLP-1 gastrointestinal-injury litigation.
Event date:
Source: jpml.uscourts.gov
GLP-1 Vision Loss (Ozempic / Wegovy NAION)
News outlets reported that over 200 federal lawsuits have been filed alleging GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro caused NAION, a rare and often permanent form of vision loss. Manufacturers reportedly dispute the claims, and plaintiffs allege they were not adequately warned of the risk.
Source: yahoo.com
GLP-1 Vision Loss (Ozempic / Wegovy NAION)
The New York Post reported that a man's claim of sudden, permanent blindness after using Ozempic is one of hundreds of lawsuits filed against GLP-1 drug makers alleging inadequate warning of vision loss risk. Separately, a Medical Economics roundup noted reporting that Wegovy may carry a higher risk of 'eye stroke' than other GLP-1 drugs, and a systematic review in the Canadian Journal of Ophthalmology examined a possible link between GLP-1 receptor agonist use and age-related macular degeneration.
Source: news.google.com
GLP-1 Vision Loss (Ozempic / Wegovy NAION)
News reports from the New York Post and other outlets describe hundreds of lawsuits against GLP-1 drug makers, with plaintiffs alleging the drugs were not adequately labeled to warn of potential vision loss. A separate report notes Wegovy may carry a higher risk of 'eye stroke' than other GLP-1 drugs, and a new systematic review examined possible links between GLP-1 receptor agonist use and age-related macular degeneration.
Source: news.google.com